title: Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults.
abstract: OBJECTIVE
  This randomized, crossover, single-dose study evaluated the relative oral bioavailability of posaconazole suspension and coprecipitate tablet formulations. Additionally, the study determined whether systemic exposure to posaconazole was affected by prandial status or by the fat content of a meal.
  
  
  METHODS
  This was a randomized, open-label, four-way crossover, single-dose study in 20 healthy men. Posaconazole pharmacokinetics were evaluated over 72 h following a single oral dose of posaconazole suspension (200 mg/5 ml) administered with a high-fat meal, a nonfat breakfast, or after a 10 h fast, or posaconazole tablets (2 x 100 mg) administered with a high-fat meal.
  
  
  RESULTS
  The posaconazole suspension showed a significant increase in bioavailability compared with the tablet (increase in AUC(0,72 h) = 137% (90% confidence interval (CI) 119%, 156% and Cmax = 123% (90% CI 104%, 146%). The mean increases in AUC(0,72 h) and Cmax values were about 400% when administered with a high-fat meal compared with administration of the suspension in the fasting state (AUC(0,72 h) 90% CI 343%, 448%; Cmax 90% CI 352%, 493%). Administration of the suspension with a nonfat meal enhanced exposure, resulting in an increase in AUC(0,72 h) of 264% (90% CI 231%, 302%) and in Cmax of 296% (90% CI 250%, 350%) relative to the fasted state.
  
  
  CONCLUSIONS
  The suspension formulation of posaconazole was associated with enhanced systemic exposure and increased relative bioavailability compared with the tablet. Food substantially enhanced the rate and extent of posaconazole absorption in healthy subjects.
authors.affiliation: Early Clinical Research and Experimental Medicine, Schering-Plough Research Institute, K-15-4-4455, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA. rachel.courtney@spcorp.com
authors.forename: Rachel
authors.initials: R
authors.lastname: Courtney
authors.forename: David
authors.initials: D
authors.lastname: Wexler
authors.forename: Elaine
authors.initials: E
authors.lastname: Radwanski
authors.forename: Josephine
authors.initials: J
authors.lastname: Lim
authors.forename: Mark
authors.initials: M
authors.lastname: Laughlin
mesh_terms: D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000935:Antifungal Agents / Q000097:blood / Q000493:pharmacokinetics*; D001682:Biological Availability; D018592:Cross-Over Studies; D005502:Food; D018565:Food-Drug Interactions; D006801:Humans; D008297:Male; D008875:Middle Aged; D013607:Tablets; D014230:Triazoles / Q000097:blood / Q000493:pharmacokinetics*
chemical_list: D000935:Antifungal Agents; D013607:Tablets; D014230:Triazoles; C101425:posaconazole